Skip to main content
main-content

Chronic kidney disease


Browse the latest news, expert commentary, and educational content on chronic kidney disease.


Highlights

02-22-2021 | Canagliflozin | News

Antihypertensive effect for canagliflozin in diabetic renal disease

The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.

01-05-2021 | Heart failure | News

Support for fluid reduction mechanism underlying SGLT2 inhibitor cardiorenal benefits

The SGLT2 inhibitor empagliflozin reduces estimated extracellular volume and plasma volume in patients who have heart failure with reduced ejection fraction, shows a randomized trial.

12-18-2020 | Dapagliflozin | Highlight | News

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

More on chronic kidney disease

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits